We have standardized the measurement of plasminogen activator inhibitor type 1 (PAl-i) activity in plasma. One-chain tissue-type plasminogen activator (t-PA; EC 3.4.21.31; final activity, 5 mt.units/mL) was incubated with plasma (final dilutions 1:4 to 1:40) in phosphate buffer (pH 7.4, ionic strength = 0.15) for 15 miri at37 "C, followed by acidification and measurement of residual t-PA activity by art amidolytic method. The PAl-i activity assay was 98% specific for PAl-i activity in samples from both pregnancy and nonpregnancy, and varied linearly with added plasma volume when the percent inhibition of t-PA was between 8% and 50%. For the standardized method, analytical recovery was 93 ± 5%, the detection limit was 1.6 arbitrary units per milliliter (1 arb. unit of PAl-i activity = inhibition of 1 mt. unit of t-PA activity), and total imprecision was 10.2 (SD 0.7) arb. units/mL (CV = 7%, n = 20). The average PAl-i activity in 10 healthy individuals drawn between 0800 and 1000 hours was 23.9 ± 15.4 arb. units/mL. Compared with the standardized assay, two of three previously described assays underestimated PAl-i activity in plasma by 77% and 85%, respectively. AddItionalKeyphrases: pregnancy . clotting . reference inteival Plasminogen activator inhibitor type 1 (PM-i) is a plasma protein that rapidly and specifically inhibits tissue-type plasminogen activator (t-PA; EC 3.4.21.31) and urokinase (1). In theory, measurement of PM-i activity in plasma should be relatively simple: an excessof pure t-PA is added to plasma, the mixture is incubated to allow the PM-i and t-PA to react, and the residual t-PA activity is determined. The difference between the initial and final t-PA activity values is equal to the PM-i activity. One arbitrary unit of PM-i activity is defined as the amount of PM-i that inhibits 1 international unit of t-PA activity under the specified analytical conditions. Seemingly simple, this assay has proven difficult to standardize. (2, 3) . The purpose of this study was not to develop a new assay for PM-i activity, but instead to standardize the current methods based on the use of t-PA (in contrast to urokinase assays). To do this, we evaluated the effects of t-PA type (one-chain vs two-chain) and concentration, pH and time of incubation, plasma dilution, and type of anticoagulant.
(Mr 70 000) for the one-chain t-PA and two bands (Mr -30 000 and 40 000) for the two-chain t-PA. The specific activity of the t-PA preparations was determined by comparison with human melanoma t-PA reference standard, lot 83/5 17 from the National Institute for Biologic Standards and Control, London, U.K. (7) . Plasminogen activator inhibitor. Human fibrosarcoma derived PM-i (product no. 109, lot no. 3, 110 mgfL) and goat polyclonal anti-PAl-i IgG (product no. 395G, lot no. 181) were from American Diagnostica Inc. Serum-free 24-h conditioned media from human umbilical vein endothelium (HuvE) stimulated with 10 mgfL endotoxin reagent was supplied by Dr. John Harlan (Seattle, WA). PM-i activity in the HUVE-conditioned media was reactivated with guanidine HC1 as described previously (8) . Briefly, the procedure was as follows. We dialyzed HuvE-conditioned media against 100 volumes of 5 mol/L guanidine HC1 reagent in PBS-Triton-X buffer [per liter: 10 mmol of sodium phosphate (pH 7.4 at 25 #{176}C), 120 mmol of NaCl, 2.7 mmol of KC1, 1 g of Triton X-100J for 4.5 h at 37 #{176}C, followed by dialysis against 4000 volumes of PBS-Triton-X buffer for 18 h at 4#{176}C. After reactivation, the HuvE-conditioned media contained 1050 arb. units of PM-i activity per milliliter.
Blood Sampling and Sample Preparation
Venous plasma used in developing the standardized assay of PM-i activity was obtained from healthy individuals. Pregnancy plasma samples were obtained during the third trimester, usually within one week of delivery. Blood samples were anticoagulated by adding 4.5 mL of whole blood to 0.5 mL of 130 mmoIIL sodium citrate solution or by adding 5 mL of whole blood to 50 tL of 150 g/L K3EDTA solution. All samples were centrifuged for 10 mm at 1000 x g at room temperature. Plasma was removed and frozen at -60 #{176}C until analyzed.
Assay Procedures
Here we describe the final assay conditions used to measure PM-i activity, then discuss the experiments performed to determine these standard conditions.
PM-i activity assay (final standardized method).
Dilute plasma 1:2, 1:5, 1:10, and 1:20 with PBS-Triton-X buffer containing 1 g of bovine albumin and 0.6 mmol of sodium aside per liter. Next, mix 200 pL of the diluted plasma with 200 ,uL of 10 mt. units/mL one-chain t-PA reagent in the same buffer as was used to dilute the plasma, and incubate for 15 mm at 37 "C to allow the t-PA and PM-i to react. The final plasma dilutions after addition of t-PA are 1:4, 1:10, 1:20, and 1:40. After incubation, add 200 pL of sodium acetate buffer (0.5 molJL, pH 4.2) to stop the reaction and destroy any a2-plasmin inhibitor. Measure residual t-PA activity as described below. Eliminate from the analysis plasma dilutions showing >50% or <8% inhibition of the original t-PA activity. Estimate total t-PA inhibitor capacity from the average of the plasma dilutions showing between 8% and 50% inhibition of the original one-chain t-PA activity.
To measure the residual t-PA activity, add 10 L of the acidified incubation solution to 250 p.L of plasminogenchromogenic substrate reagent [per liter: 75 mmol of Tris acetate buffer (pH 8.2 at 37 #{176}C), 1 g of Triton X-100, 0.50 tmol of human glu-plasminogen, 0.3 mmol of r-valyl-i..-phenylalanyl-iAysyl-p-nitroaniline substrate, and 80 mg of CNBr-cleaved fibrinogen], and incubate at 37 #{176}C for 60 miii (9) . Stop the reaction by adding 0.1 volume of 500 g/L acetic acid reagent to the reaction solution, then measure the absorbance at 405 rim [we used a Cobas Bio centrifugal analyzer (Roche Analytical Instruments, Nutley, NJ)]. Determine the residual t-PA activity by comparing the change in absorbance of the plasma-containing samples with that of the t-PA standards (no plasma added).
Comparison of different incubation solutions. We used two different incubation buffers to dilute the plasma samples and t-PA standards: PBS-Triton-X buffer containing i g of bovine albumin and 0.6 mmol of sodium aside per liter or 75 mmoliL Ti-is acetate buffer (pH 8.2 at 37#{176}C), containing 1 g of Triton X-iOO, 1 g of bovine albumin, and 0.6 mmol of sodium aside per liter. Final dilutions of plasma after t-PA was added ranged from 1:5 to 1:1280. To determine whether plasmin was being generated during the initial incubation step from plasminogen in the patient's plasma, we added a plasmin-sensitive chromogenic substrate, n-valyl-L-phenylalanyl-L-lysyl-p-nitroaniline (0.3 mmol/L final concentration), to the initial incubation solutions described above. The plasma and t-PA were then diluted with these modified buffers, combined, and incubat-. ed for 60 mm at 37 "C. Plasmun formation during the incubation was monitored by measuring the absorbance of the solution at 405 mm.
Immunoinhibition of PM-i activity. PAl-i-specific activity in samples of diluted plasma and in a preparation of purified PM-i was immunoinhibited by incubating the sample with anti-PM-i IgG, 20 mg/L, for 10 mm at 37 #{176}C before adding the t-PA. This inhibits >98% of the PM-i activity in a sample. We estimated PM-i specific activity as the difference between total t-PA inhibition and t-PA inhibition with a saturating concentration (20 mg/L) of anti-PM-i antibody.
Incubation time. "Optimum incubation time" was defined as the minimum time necessary for the PM-i activity in the sample and the added t-PA to react to completion. To determine this, we incubated diluted plasma and t-PA as described above for 5, 10, 15, and 20 mm, then acidified the solution and measured its residual t-PA activity. The reaction was defined as being complete when there was <3% change in the residual t-PA activity between two incubation times.
Assay linearity.
To determine the linear range of the assay, we measured residual t-PA activity after adding increasing dilutions of plasma or purified PAl-i as described above. To determine whether addition of different concentrations of t-PA activity would alter the estimated activity of PM-i, we incubated 200 1zL of diluted plasma with 200 1zLoft-PA solutions containing 8, 10, 12, or 14 mt.units/mL (3) .
Comparison of EDTA-vs citrate-anticoagulated plasma.
We measured PM-i activity in paired samples of EDTAand citrate-anticoagulated plasma obtained from 10 healthy individuals between 0800 and 1000 hours. Results for the citrate-anticoagulated samples were corrected for dilution by the citrate solution by comparing the hematocrit in the EDTA-anticoagulated blood with the hematocrit in the citrate-anticoagulated blood.
Comparison of one-chain vs two-chain t-PA: specificity for PM-i activity. We used two methods to determine the type of t-PA most specific for PM-i activity in plasma. First, we determined total t-PA inhibition with both one-chain and two-chain t-PA as the standard in samples of nonpregnancy plasma and in samples of plasma from women in the third trimester of pregnancy (10). The ratio of total t-PA inhibi- tion measured by using the one-chain t-PA as compared with two-chain t-PA was calculated for each pair of assays. Next, we measured total t-PA inhibition in the same set of pregnancy and nonpregnancy samples after immumoinhibition of the PM-i activity in each sample with a saturating concentration (20 mg/L) of anti-PM-i IgG.
Analytical Recovery, Detection Limit, and Imprecision
We determined analytical recovery of PM-i activity added to plasma by adding guanidine HC1-reactivated, HUvE-conditioned media to either PBS-Triton-X buffer or unsupplemented monpregnancy plasma, then quantifying PM-i activity by the standardized method described above. The detection limit of the assay was defined as the minimum PM-i activity in fourfold diluted plasma that could be reproducibly measured as differing from the blank containing no PM-i activity. Within-run and total imprecision were estimated by repeated assay of nonpregnancy plasma.
Comparison of Methods for Measuring PAl-i Activity
We compared the standardized assay of PAl-i activity with three previously described t-PA inhibitor assays (2) (3) (4) . Using each of four assays, we measured total t-PA inhibited in a single sample of purified PM-i and in 10 samples of plasma from healthy individuals. Statistics. We tested group distributions for normality by using the Wilk-Shapiro test and by determining the coefficients of skew and kurtosis. Normal distributions are reported as mean ± SD. Differences between groups were tested for significance by using two-tailed Student's t-tests (paired or unpaired, depending on the specific groups). Linear regressions and correlation coefficients were calculated by conventional methods. Besides the slopeand SD of the slope, and intercept and SD of the intercept, we also calculated the SD of the regression (SDR).
Results
Analytical recovery of t-PA activity during the incubation step. During the initial incubation step, the PM-i in the sample reacts with the added t-PA. This assay is based on the assumption that, if the sample contains no PM-i activity, all the original t-PA activity added will be accounted for. We tested this assumption for both one-chain t-PA and two-chain t-PA by using two different solutions to dilute the plasma sample and t-PA: PBS buffer (pH 7.4, ionic strength = 0.15) and Ti-is buffer (pH 8.2 at 37 "C, ionic strength = 0.03). Plasma samples with <4 arb. units of PM-1 activity per milliliter were used in the experiment. As expected, using two-chain t-PA and either of the buffers described above, addition of progressively less plasma to the assay resulted in a progressive increase in residual t-PA activity, until essentially all the original t-PA activity was recovered (Figure lA) . Use of one-chain t-PA demonstrated a similar pattern when PBS buffer was used to dilute the plasma and t-PA (see Figure 1B) . In contrast, when we incubated one-chain t-PA and plasma in the Tris buffer, we recovered increased t-PA activity, i.e., more t-PA activity than was originally added. Previous studies have found that one-chain t-PA is two-to threefold less active than two-chain t-PA (9, 11), and that one-chain t-PA is converted into two-chain t-PA by plasmin (12). Thus the increase in t-PA recovery when one-chain t-PA is added to plasma in the Ti-is buffer might result from the conversion of one-chain t-PA into the two-chain form by plasmin generated from plasminogen in the patient's plasma during the incubation step. To determine whether plasmin was being formed, we added 0.3 mmol of the plasmin-sensitive chromogenic substrate D-valyl-L-phenylalanyl-i.-lysyl-p-nitroaniline per liter to both the PBS and Ti-is buffers used in the incubation step. Plasma and t-PA were diluted as before with these modified buffers and incubated together for 60 mm at 37 "C. As shown in Figure  2 , on using Ti-is buffer with either one-chain or two-chain t-PA there was an increase in absorbance, indicating the presence of plasmin activity during the incubation step. There was essentially no increase in absorbance, and thus no plasmin activity, when we used the PBS buffer. To suppress plasmin formation during the incubation step, we selected the PBS buffer as the standard buffer for the PM-i activity assay. Linearity of t-PA inhibition. Inhibition of t-PA activity varied linearly with the concentration of purified PM-i and the volume of plasma added until -50% the original t-PA was inhibited (Figure 4) . When >50% of the original t-PA was inhibited, the assay became progressively nonlinear and began to underestimate the concentration of PM-i activity in the sample. Added t-PA activity was never completely inhibited. Even when we added a twofold excess of PM-i activity (as compared with t-PA activity) to the assay, a small but measurable t-PA activity was still found. We confirmed by immunoinhibition, using anti-t-PA antibodies,that this small residual activity was caused by t-PA. Figure 5 shows plots of original vs residual t-PA activity for a range of plasma dilutions and initial added t-PA concentrations. Use of final plasma dilutions from fivefold to 20-fold yielded parallel curves, indicating that varying the final concentration of t-PA activity in the assay from 4 to 7 nit. units/mL did not change the estimated PM-i activity in the sample. When twofold-diluted plasma was used, >50% of the original t-PA was inhibited and the curve became nonparallel with the other dilution curves, again indicating that the assay is inaccurate when >50% of the original t-PA activity is inhibited.
PLASMA VOLUME (uL) tmPBS [per liter, 10 mmol of sodium phosphate (pH 7.4), 2.7 mmol of KCI, 120mmolof NaCI, 1 got Triton X-100, 1 got bovine albumin,and 0.6 mmol of sodium aside) was supplementedwith guanidine-HCI-reactivatedPAl-i from humanumbilical vein endothelial cell-conditioned media. units/mL, as compared with two-chain t-PA, 38.0 (SD 21.9) arb. units/mL (P = 0.0001, paired t-test). The ratio of PM-i activity determined by using one-chain vs two-chain t-PA was 1.00 (SD 0.07) for the nonpregnancy samples and 0.81 (SD 0.10) for the pregnancy samples (P = 0.0001, unpaired t-test). Thus, on average, pregnancy plasma inhibited significantly more two-chain t-PA than one-chain t-PA as compared with nonpregnancy plasma.
Fig. 4. Linearity of t-PA inhibition vs the amount of purified PAl-i or volumeof plasmaaddedto the assay
When measured with either one-chain t-PA or two-chain t-PA, anti-PM-i
IgG inhibited >98% of the total PAl activity in nonpregnancy plasma. When we used one-chain t-PA, anti-PM-i IgG inhibited more than 98% of the total PAl activity in pregnancy plasma. In contrast, when twochain t-PA was used in the assay, pregnancy plasma contained up to i2 arb. units of PM activity per milliliter that could not be inhibited with anti-PM-i IgG. This suggests that other t-PA inhibitors, such as PM-2, are interfering in the assay when PM activity is measured in pregnancy plasma with two-chain t-PA, and that the assay is specific for PM-i activity when one-chain t-PA is used.
The current assay is most specific for PM-i activity when the plasma contains >5 arb. units of PM-i activity per milliliter. Samples with <5 arb. units/mL require final plasma dilutions of fourfold or less to detect t-PA inhibition accurately. Irnmunoinhibition studies indicated that PM-i activity may be overestimated by 1 to 4 arb. unitslmL in some low-activity plasma samples. This was not the case in higher activity samples that used final plasma dilutions of 10-fold or greater.
Analytical recovery, detection limit, and imprecision of the standardized assay. On the basis of the results presented above we developed a standardized assay for the measurement of PM-i activity (see Methods section for details).
Analytical
recovery of PM-i activity from plasma averaged 93% (Table i) . As discussed above, estimation of PM-i activity was inaccurate when <8% of the original t-PA activity was inhibited. Thus, using this 8% limit and a minimum final plasma dilution of fourfold, the detection limit (i.e., the lowest PM-i activity detectable in plasma) was approximately 1.6 arb. units/mL. In our laboratory, the PM-i activity assay is designed to measure up to four plasma samples per run. Within-run imprecision was 19.5 (SD 0.3) arb. units/mL (CV = 2%, n = 4), and total imprecision was 10.2 (SD 0.7) arb. units/mL (CV = 7%, n = 20).
Comparison of four assays for PM-i activity. The standardized method for measuring PM-i activity described above was compared with three other assays for PM-i activity (Table 2 and Figure 6) Mean (and SD) results for citrated plasma from 10 healthy nonpregnant individualsdrawn between 0800 and 1000 hours.
t'Total t-PA inhibited for a single sample of purified PAl-i. Of the four assays, Method C produced the lowest estimates of PM-i activity, on average, 85% lower than the standardized method (P = 0.00 1, paired t-test), and correlated most poorly (r = 0.945) with the standardized method results. In both the standardized method and Method C, anti-PM-i IgG was used to evaluate the PM-i specificity of the assay. In the standardized assay, more than 98% of the t-PA inhibition of nonpregnancy plasma was due to PM-i activity, whereas for Method C only 27% to 60% of the apparent t-PA inhibitory activity was ascribable to PM-i specific activity. As originally described, Methods A and B were not specific for PM-i activity; instead they measured total t-PA inhibition in plasma.
Discussion
Previous studies indicate that PM-i plays an important role in the development of arterial and venous thromboembolism (1). Unfortunately, research in this area is hampered by the lack of a standardized assay, resulting in wide variations in the reported concentration of PM-i activity in plasma (2) (3) (4) (13) (14) (15) (16) (17) (18) (19) (20) . As shown in Table 3 Overall, our method was simple, requiring only three steps: incubation of t-PA and PM-i, acidification, and (19) 6 M&F tmAll resultsshownare fromstudies published in 1988and are for samples collectedfromthe subiectsin the morning. measurement of residual t-PA activity. The assay demonstrated good analytical recovery of PM-i activity (93%), a low detection limit (1.6 arb. units/mL), and better precision than previous methods (3,4) . In assessing the assay of PM-i activity, we found that the ratio of t-PA activity to PM-i activity is of crucial importance in determining the accuracy and precision of the method. First, t-PA activity must be added in excess or the assay will underestimate PM-i activity. We add at least 20 mt. units of t-PA activity per milliliter of plasma. Addition of too much t-PA activity, though, decreases the precision of the assay, because only a small fraction of the original t-PA is inhibited. We estimated PM-i activity in plasma dilutions showing inhibition of from 8% to 50% of the original t-PA added. Inhibition of <8% of the original t-PA activity was difficult to measure reproducibly, resulting in imprecise PM-i activity estimates. Inhibition of >50% of the added t-PA resulted in underestimates of the PM-i activity as compared with higher dilutions of the same samples of plasma. Use of less t-PA activity in the incubation step and failure to predilute the plasma sample adequately may have contributed to the underestimates of PM-i activity in comparison Methods B andC.
We assessedthe specificity of the standardized method by measuring t-PA inhibition in the presence and absence of a saturating amount of anti-PM-i IgG. When measured with one-chain t-PA, we found that more than 98% of the rapid t-PA inhibitory capacity of both pregnancy and nonpregnancy plasma was attributable to PM-i activity, indicating that the standardized method is essentially specific for PMi activity in plasma. This specificity is somewhat decreased for samples with PM-i activities <5 arb. units/mL, probably as a result of the high concentration of plasma used in the assay. Clinically, it is thought that high PM-i activities lead to an increased risk of thromboembolism. Thus, low PM-i activity is currently of less interest clinically than high PM-i activity. Owing to the increased expense and time required, routine us of anti-PM-i
IgG to prove specificity is probably not justified.
In comparing the standardized assay with three other previously described assays, we found that Method A produced results that were similar to those by our method (3). Speiser et al. (3) suggested plasma should be diluted at least 10-fold before being assayed. We found that PAl-i activity could still be estimated in plasma diluted <10-fold, but that PM-i activity may be somewhat overestimated under these conditions. They reported that t-PA inhibition was maximum after a 10-nun incubation at 25 #{176}C; longer incubation times resulted in less t-PA inhibition. They suggested this might be due to proteolytic inactivation of PM-i. We found no evidence of either a decrease in t-PA inhibition or of a loss of PAl-i activity with longer incubation times (up to 60 mm). Although their method was not shown to be specific for PM-i activity, our results indicate that most of the t-PA inhibition in their assay was caused by PM-i if one-chain t-PA is used.
Comparison Method B produced underestimates of total t-PA inhibition compared with the standardized method (2, 18) . Method B starts with undiluted plasma and less t-PA is added, resulting in a t-PAlplasma ratio of 2 mt.units of t-PA per milliliter of plasma, a ratio at least 10-fold less than in the standardized method.
Method C produced the lowest estimates of PM-i activity in plasma (4). In this method, there is no dilution of plasma or any incubation step. Instead, plasma and t-PA are added directly to the plasminogen-chromogenic substrate reagent used to measure residual t-PA activity. This results in complicated reaction kinetics, because t-PA is reacting with PM-i, plasminogen, and fibrin during the t-PA activity assay. In addition, lack of plasma acidification and larger plasma volumes result in up to 50 times more a2-plasmin inhibitor being present in their assay (9). a2-Plasmin inhibitor can interfere in the t-PA activity measurements by destroying plasmin formed during the assay (9).
We conclude that assay conditions have a major effect on the measurement of PM-i activity in plasma. Owing to suboptimal assay conditions, two of three previously described assays significantly underestimated PM-i activity in plasma. Our results lead us to propose a standardized assay that is relatively simple and highly specific for PM-i activity.
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